Critical role of keratinocytes and protease-activated receptor 2 in secondary lymphedema development

Abstract

Background: Secondary lymphedema is a common complication of cancer treatment and epidermal changes are recognised as histological hallmarks of secondary lymphedema; however, the role of keratinocytes in the pathophysiology of this disease remains unclear.

Methods: Hyperkeratosis, up-regulation of protease-activated receptor 2 (PAR2) and Th2-inducing cytokines were assessed in biopsy specimens from patients with unilateral breast cancer-related lymphedema (BCRL) and in a mouse model of lymphedema. PAR2 inhibition using global PAR2 knockout, keratinocyte-specific PAR2 KO and bone marrow chimera models, or keratinocyte proliferation inhibition using a topical formulation of Teriflunomide (TF), was analysed in mouse models of lymphedema. We also assessed the direct effects of patient-derived lymphedema lymph fluid (LF) on keratinocyte activation in vitro.

Results: Hyperkeratosis, expression of Th2-inducing cytokines and PAR2 were significantly increased in BCRL patient biopsies and mouse models. Keratinocytes play a primary role in the lymphedema development by producing T helper 2 (Th2)-inducing cytokines. Specifically, keratinocyte proliferation and PAR2 expression are early responses following lymphatic injury and regulate the expression of Th2-inducing cytokines, the migration of Langerhans cells and the infiltration of Th2-differentiated T cells into the skin. Deficiency of PAR2 or topical inhibition of thymic stromal lymphopoietin rescues secondary lymphedema by reducing Th2 inflammation. Inhibition of PAR2 activation with a small-molecule inhibitor, or the proliferation of the inhibitor TF, prevents activation of keratinocytes stimulated with lymphedema fluid. Finally, topical TF is highly effective in reducing swelling, fibrosis and inflammation and the overall pathology of lymphedema.

Conclusions: Our findings suggest that lymphedema is a chronic inflammatory skin disease, and topically targeting keratinocyte inhibition may be a clinically effective therapy for this condition.

Key points:

Keywords

hyperkeratosis / keratinocyte / PAR2 / secondary lymphedema / teriflunomide / Th2-inducing cytokines / TSLP

References

[1] Szuba A, Rockson SG. Lymphedema: anatomy, physiology and pathogenesis. Vasc Med. 1997; 2(4): 321–326. https://doi.org/10.1177/1358863X9700200408

[2] Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer. 1998; 83(12 Suppl American): 2776–2781. https://doi.org/10.1002/(sici)1097-0142(19981215)83:12b+<2776::aid-cncr25>3.0.co;2-v

[3] Dayan JH, Ly CL, Kataru RP, Mehrara BJ. Lymphedema: pathogenesis and novel therapies. Annu Rev Med. 2018; 69: 263–276. https://doi.org/10.1146/annurev-med-060116-022900

[4] Vignes S, Porcher R, Arrault M, Dupuy A. Long-term management of breast cancer-related lymphedema after intensive decongestive physiotherapy. Breast Cancer Res Treat. 2007; 101(3): 285–290. https://doi.org/10.1007/s10549-006-9297-6

[5] Chang DW, Dayan J, Greene AK, et al. Surgical treatment of lymphedema: a systematic review and meta-analysis of controlled trials. results of a consensus conference. Plast Reconstr Surg. 2021; 147(4): 975–993. https://doi.org/10.1097/PRS.0000000000007783

[6] Ly CL, Cuzzone DA, Kataru RP, Mehrara BJ. Small numbers of CD4+ T cells can induce development of lymphedema. Plast Reconstr Surg. 2019; 143(3): 518e–526e. https://doi.org/10.1097/PRS.0000000000005322

[7] Garcia Nores GD, Ly CL, Cuzzone DA, et al. CD4(+) T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema. Nat Commun. 2018; 9(1): 1970. https://doi.org/10.1038/s41467-018-04418-y

[8] Gardenier JC, Kataru RP, Hespe GE, et al. Topical tacrolimus for the treatment of secondary lymphedema. Nat Commun. 2017; 8:14345. https://doi.org/10.1038/ncomms14345

[9] Ogata F, Fujiu K, Matsumoto S, et al. Excess lymphangiogenesis cooperatively induced by macrophages and CD4(+) T cells drives the pathogenesis of lymphedema. J Invest Dermatol. 2016; 136(3): 706–714. https://doi.org/10.1016/j.jid.2015.12.001

[10] Gousopoulos E, Proulx ST, Bachmann SB, et al. Regulatory T cell transfer ameliorates lymphedema and promotes lymphatic vessel function. JCI Insight. 2016; 1(16):e89081. https://doi.org/10.1172/jci.insight.89081

[11] Yuan Y, Arcucci V, Levy SM, Achen MG. Modulation of immunity by lymphatic dysfunction in lymphedema. Front Immunol. 2019; 10:76. https://doi.org/10.3389/fimmu.2019.00076

[12] Hara H, Mihara M, Anan T, et al. Pathological investigation of acquired lymphangiectasia accompanied by lower limb lymphedema: lymphocyte infiltration in the dermis and epidermis. Lymphat Res Biol. 2016; 14(3): 172–180. https://doi.org/10.1089/lrb.2016.0016

[13] Nakamura K, Radhakrishnan K, Wong YM, Rockson SG. Anti-inflammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufficiency in mice. PLoS One. 2009; 4(12):e8380. https://doi.org/10.1371/journal.pone.0008380

[14] Rockson SG, Tian W, Jiang X, et al. Pilot studies demonstrate the potential benefits of antiinflammatory therapy in human lymphedema. JCI Insight. 2018; 3(20):e123775. https://doi.org/10.1172/jci.insight.123775

[15] Avraham T, Zampell JC, Yan A, et al. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB J. 2013; 27(3): 1114–1126. https://doi.org/10.1096/fj.12-222695

[16] Zampell JC, Yan A, Elhadad S, Avraham T, Weitman E, Mehrara BJ. CD4(+) cells regulate fibrosis and lymphangiogenesis in response to lymphatic fluid stasis. PLoS One. 2012; 7(11):e49940. https://doi.org/10.1371/journal.pone.0049940

[17] Ghanta S, Cuzzone DA, Torrisi JS, et al. Regulation of inflammation and fibrosis by macrophages in lymphedema. Am J Physiol Heart Circ Physiol. 2015; 308(9): H1065–H1077. https://doi.org/10.1152/ajpheart.00598.2014

[18] Ly CL, Nores GDG, Kataru RP, Mehrara BJ. T helper 2 differentiation is necessary for development of lymphedema. Transl Res. 2019; 206: 57–70. https://doi.org/10.1016/j.trsl.2018.12.003

[19] Savetsky IL, Ghanta S, Gardenier JC, et al. Th2 cytokines inhibit lymphangiogenesis. PLoS One. 2015; 10(6):e0126908. https://doi.org/10.1371/journal.pone.0126908

[20] Mehrara BJ, Park HJ, Kataru RP, et al. Pilot study of anti-Th2 immunotherapy for the treatment of breast cancer-related upper extremity lymphedema. Biology (Basel). 2021; 10(9):934. https://doi.org/10.3390/biology10090934

[21] Furlong-Silva J, Cross SD, Marriott AE, et al. Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor-mediated lymphangiogenesis. J Clin Invest. 2021; 131(5):e140853. https://doi.org/10.1172/JCI140853

[22] Horton J, Klarmann-Schulz U, Stephens M, et al. The design and development of a multicentric protocol to investigate the impact of adjunctive doxycycline on the management of peripheral lymphoedema caused by lymphatic filariasis and podoconiosis. Parasit Vectors. 2020; 13(1): 155. https://doi.org/10.1186/s13071-020-04024-2

[23] Domaszewska-Szostek A, Zaleska M, Olszewski WL. Hyperkeratosis in human lower limb lymphedema: the effect of stagnant tissue fluid/lymph. J Eur Acad Dermatol Venereol. 2016; 30(6): 1002–1008. https://doi.org/10.1111/jdv.13565

[24] De Cock HE, Affolter VK, Wisner ER, Ferraro GL, MacLachlan NJ. Progressive swelling, hyperkeratosis, and fibrosis of distal limbs in Clydesdales, Shires, and Belgian draft horses, suggestive of primary lymphedema. Lymphat Res Biol. 2003; 1(3): 191–199. https://doi.org/10.1089/153968503768330238

[25] Carretero M, Guerrero-Aspizua S, Illera N, et al. Differential features between chronic skin inflammatory diseases revealed in skin-humanized psoriasis and atopic dermatitis mouse models. J Invest Dermatol. 2016; 136(1): 136–145. https://doi.org/10.1038/JID.2015.362

[26] Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol. 2012; 34(1): 133–149. https://doi.org/10.1007/s00281-011-0289-1

[27] Athari SS. Targeting cell signaling in allergic asthma. Signal Transduct Target Ther. 2019; 4: 45. https://doi.org/10.1038/s41392-019-0079-0

[28] Chieosilapatham P, Kiatsurayanon C, Umehara Y, et al. Keratinocytes: innate immune cells in atopic dermatitis. Clin Exp Immunol. 2021; 204(3): 296–309. https://doi.org/10.1111/cei.13575

[29] MacFarlane ER, Donaldson PJ, Grey AC. UV light and the ocular lens: a review of exposure models and resulting biomolecular changes. Front Ophthalmol (Lausanne). 2024; 4:1414483. https://doi.org/10.3389/fopht.2024.1414483

[30] Hatano Y, Elias PM. “Outside-to-inside,” “inside-to-outside,” and “intrinsic” endogenous pathogenic mechanisms in atopic dermatitis: keratinocytes as the key functional cells involved in both permeability barrier dysfunction and immunological alterations. Front Immunol. 2023; 14:1239251. https://doi.org/10.3389/fimmu.2023.1239251

[31] Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. J Clin Invest. 2019; 129(4): 1441–1451. https://doi.org/10.1172/JCI124606

[32] Divekar R, Kita H. Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation. Curr Opin Allergy Clin Immunol. 2015; 15(1): 98–103. https://doi.org/10.1097/ACI.0000000000000133

[33] Furio L, de Veer S, Jaillet M, et al. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome. J Exp Med. 2014; 211(3): 499–513. https://doi.org/10.1084/jem.20131797

[34] Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Targeting IL-4 for the treatment of atopic dermatitis. Immunotargets Ther. 2020; 9: 151–156. https://doi.org/10.2147/ITT.S260370

[35] Zhang X, Yin M, Zhang LJ. Keratin 6, 16 and 17-critical barrier alarmin molecules in skin wounds and psoriasis. Cells. 2019; 8(8):807. https://doi.org/10.3390/cells8080807

[36] Alam H, Sehgal L, Kundu ST, Dalal SN, Vaidya MM. Novel function of keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells. Mol Biol Cell. 2011; 22(21): 4068–4078. https://doi.org/10.1091/mbc.E10-08-0703

[37] Stefansson K, Brattsand M, Roosterman D, et al. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J Invest Dermatol. 2008; 128(1): 18–25. https://doi.org/10.1038/sj.jid.5700965

[38] Jairaman A, Yamashita M, Schleimer RP, Prakriya M. Store-operated Ca2+ release-activated Ca2+ channels regulate PAR2-activated Ca2+ signaling and cytokine production in airway epithelial cells. J Immunol. 2015; 195(5): 2122–2133. https://doi.org/10.4049/jimmunol.1500396

[39] Fan M, Fan X, Lai Y, et al. Protease-activated receptor 2 in inflammatory skin disease: current evidence and future perspectives. Front Immunol. 2024; 15:1448952. https://doi.org/10.3389/fimmu.2024.1448952

[40] Baik JE, Park HJ, Kataru RP, et al. TGF-beta1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation. Clin Transl Med. 2022; 12(6):e758. https://doi.org/10.1002/ctm2.758

[41] Frateschi S, Camerer E, Crisante G, et al. PAR2 absence completely rescues inflammation and ichthyosis caused by altered CAP1/Prss8 expression in mouse skin. Nat Commun. 2011; 2: 161. https://doi.org/10.1038/ncomms1162

[42] Furio L, Pampalakis G, Michael IP, Nagy A, Sotiropoulou G, Hovnanian A. KLK5 inactivation reverses cutaneous hallmarks of netherton syndrome. PLoS Genet. 2015; 11(9):e1005389. https://doi.org/10.1371/journal.pgen.1005389

[43] Shpacovitch V, Feld M, Hollenberg MD, Luger TA, Steinhoff M. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol. 2008; 83(6): 1309–1322. https://doi.org/10.1189/jlb.0108001

[44] Hamilton JR, Frauman AG, Cocks TM. Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res. 2001; 89(1): 92–98. https://doi.org/10.1161/hh1301.092661

[45] Wilson SR, Thé L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013; 155(2): 285–295. https://doi.org/10.1016/j.cell.2013.08.057

[46] Park BB, Choi JW, Park D, et al. Structure-activity relationships of baicalein and its analogs as novel TSLP inhibitors. Sci Rep. 2019; 9(1): 8762. https://doi.org/10.1038/s41598-019-44853-5

[47] Zhu Y, Peng X, Zhang Y, Lin J, Zhao G. Baicalein protects against aspergillus fumigatus keratitis by reducing fungal load and inhibiting TSLP-induced inflammatory response. Invest Ophthalmol Vis Sci. 2021; 62(6):26. https://doi.org/10.1167/iovs.62.6.26

[48] Ly CL, Kataru RP, Mehrara BJ. Inflammatory manifestations of lymphedema. Int J Mol Sci. 2017; 18(1):171. https://doi.org/10.3390/ijms18010171

[49] Gordon EM, Yao X, Xu H, et al. Apolipoprotein E is a concentration-dependent pulmonary danger signal that activates the NLRP3 inflammasome and IL-1beta secretion by bronchoalveolar fluid macrophages from asthmatic subjects. J Allergy Clin Immunol. 2019; 144(2):426–441 e3. https://doi.org/10.1016/j.jaci.2019.02.027

[50] Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem. 2000; 275(34): 26333–26342. https://doi.org/10.1074/jbc.M002941200

[51] Elmariah SB, Reddy VB, Lerner EA. Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist. PLoS One. 2014; 9(6):e99702. https://doi.org/10.1371/journal.pone.0099702

[52] Bock A, Tucker N, Kelher MR, et al. alpha-Enolase causes proinflammatory activation of pulmonary microvascular endothelial cells and primes neutrophils through plasmin activation of protease-activated receptor 2. Shock. 2015; 44(2): 137–142. https://doi.org/10.1097/SHK.0000000000000394

[53] Gobel K, Asaridou CM, Merker M, et al. Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release. Proc Natl Acad Sci USA. 2019; 116(1): 271–276. https://doi.org/10.1073/pnas.1810020116

[54] Oe Y, Hayashi S, Fushima T, et al. Coagulation factor Xa and protease-activated receptor 2 as novel therapeutic targets for diabetic nephropathy. Arterioscler Thromb Vasc Biol. 2016; 36(8): 1525–1533. https://doi.org/10.1161/ATVBAHA.116.307883

[55] Julovi SM, Xue M, Dervish S, Sambrook PN, March L, Jackson CJ. Protease activated receptor-2 mediates activated protein C-induced cutaneous wound healing via inhibition of p38. Am J Pathol. 2011; 179(5): 2233–2242. https://doi.org/10.1016/j.ajpath.2011.07.024

[56] Scott G, Deng A, Rodriguez-Burford C, et al. Protease-activated receptor 2, a receptor involved in melanosome transfer, is upregulated in human skin by ultraviolet irradiation. J Invest Dermatol. 2001; 117(6): 1412–1420. https://doi.org/10.1046/j.0022-202x.2001.01575.x

[57] Kumar V, Behr M, Kiritsi D, et al. Keratin-dependent thymic stromal lymphopoietin expression suggests a link between skin blistering and atopic disease. J Allergy Clin Immunol. 2016; 138(5): 1461–1464.e6. https://doi.org/10.1016/j.jaci.2016.04.046

[58] Wiese MD, Rowland A, Polasek TM, Sorich MJ, O'Doherty C. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol. 2013; 9(8): 1025–1035. https://doi.org/10.1517/17425255.2013.800483

[59] Ruckemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem. 1998; 273(34): 21682–21691. https://doi.org/10.1074/jbc.273.34.21682

[60] Matsui T, Amagai M. Dissecting the formation, structure and barrier function of the stratum corneum. Int Immunol. 2015; 27(6): 269–280. https://doi.org/10.1093/intimm/dxv013

[61] Werner S, Smola H. Paracrine regulation of keratinocyte proliferation and differentiation. Trends Cell Biol. 2001; 11(4): 143–146. https://doi.org/10.1016/s0962-8924(01)01955-9

[62] Ni X, Lai Y. Keratinocyte: a trigger or an executor of psoriasis? J Leukoc Biol. 2020; 108(2): 485–491. https://doi.org/10.1002/jlb.5mr0120-439r

[63] Oveland E, Karlsen TV, Haslene-Hox H, et al. Proteomic evaluation of inflammatory proteins in rat spleen interstitial fluid and lymph during LPS-induced systemic inflammation reveals increased levels of ADAMST1. J Proteome Res. 2012; 11(11): 5338–5349. https://doi.org/10.1021/pr3005666

[64] Hansen KC, D'Alessandro A, Clement CC, Santambrogio L. Lymph formation, composition and circulation: a proteomics perspective. Int Immunol. 2015; 27(5): 219–227. https://doi.org/10.1093/intimm/dxv012

[65] Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J. 2019; 17: 4. https://doi.org/10.1186/s12959-019-0194-8

[66] Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009; 206(5): 1135–1147. https://doi.org/10.1084/jem.20082242

[67] Braz JM, Dembo T, Charruyer A, Ghadially R, Fassett MS, Basbaum AI. Genetic priming of sensory neurons in mice that overexpress PAR2 enhances allergen responsiveness. Proc Natl Acad Sci USA. 2021; 118(8):e2021386118. https://doi.org/10.1073/pnas.2021386118

[68] Briot A, Lacroix M, Robin A, Steinhoff M, Deraison C, Hovnanian A. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol. 2010; 130(12): 2736–2742. https://doi.org/10.1038/jid.2010.233

[69] Barr TP, Garzia C, Guha S, et al. PAR2 pepducin-based suppression of inflammation and itch in atopic dermatitis models. J Invest Dermatol. 2019; 139(2): 412–421. https://doi.org/10.1016/j.jid.2018.08.019

[70] Derian CK, Eckardt AJ, Andrade-Gordon P. Differential regulation of human keratinocyte growth and differentiation by a novel family of protease-activated receptors. Cell Growth Differ. 1997; 8(7): 743–749.

[71] Nadeau P, Henehan M, De Benedetto A. Activation of protease-activated receptor 2 leads to impairment of keratinocyte tight junction integrity. J Allergy Clin Immunol. 2018; 142(1):281–284 e7. https://doi.org/10.1016/j.jaci.2018.01.007

[72] Park HJ, Shin J, Sarker A, et al. TGF-beta-mediated epithelial-mesenchymal transition of keratinocytes promotes fibrosis in secondary lymphedema. JCI Insight. 2025; 10(17):e192890. https://doi.org/10.1172/jci.insight.192890

[73] Campbell AC, Baik JE, Sarker A, et al. Breast cancer-related lymphedema results in impaired epidermal differentiation and tight junction dysfunction. J Invest Dermatol. 2025; 145(1):85–97 e4. https://doi.org/10.1016/j.jid.2024.05.017

[74] Leyva-Castillo JM, Hener P, Jiang H, Li M. TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. J Invest Dermatol. 2013; 133(1): 154–163. https://doi.org/10.1038/jid.2012.239

[75] Yoo J, Omori M, Gyarmati D, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med. 2005; 202(4): 541–549. https://doi.org/10.1084/jem.20041503

[76] Lai JF, Thompson LJ, Ziegler SF. TSLP drives acute TH2-cell differentiation in lungs. J Allergy Clin Immunol. 2020; 146(6):1406–1418 e7. https://doi.org/10.1016/j.jaci.2020.03.032

[77] Howell MD, Fairchild HR, Kim BE, et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol. 2008; 128(9): 2248–2258. https://doi.org/10.1038/jid.2008.74

[78] Lee SH, Bae IH, Choi H, et al. Ameliorating effect of dipotassium glycyrrhizinate on an IL-4- and IL-13-induced atopic dermatitis-like skin-equivalent model. Arch Dermatol Res. 2019; 311(2): 131–140. https://doi.org/10.1007/s00403-018-1883-z

[79] Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int J Mol Sci. 2020; 21(15):5382. https://doi.org/10.3390/ijms21155382

[80] Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009; 129(3): 742–751. https://doi.org/10.1038/jid.2008.295

[81] Hanel KH, Cornelissen C, Luscher B, Baron JM. Cytokines and the skin barrier. Int J Mol Sci. 2013; 14(4): 6720–6745. https://doi.org/10.3390/ijms14046720

[82] Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014; 74(6): 659–674. https://doi.org/10.1007/s40265-014-0212-x

[83] Hail N, Jr., Chen P, Kepa JJ, Bushman LR. Evidence supporting a role for dihydroorotate dehydrogenase, bioenergetics, and p53 in selective teriflunomide-induced apoptosis in transformed versus normal human keratinocytes. Apoptosis. 2012; 17(3): 258–268. https://doi.org/10.1007/s10495-011-0667-0

[84] Hail N, Jr., Chen P, Rower J, Bushman LR. Teriflunomide encourages cytostatic and apoptotic effects in premalignant and malignant cutaneous keratinocytes. Apoptosis. 2010; 15(10): 1234–1246. https://doi.org/10.1007/s10495-010-0518-4

[85] Hsu JF, Yu RP, Stanton EW, Wang J, Wong AK. Current advancements in animal models of postsurgical lymphedema: a systematic review. Adv Wound Care (New Rochelle). 2022; 11(8): 399–418. https://doi.org/10.1089/wound.2021.0033

[86] Grada AA, Phillips TJ. Lymphedema: pathophysiology and clinical manifestations. J Am Acad Dermatol. 2017; 77(6): 1009–1020. https://doi.org/10.1016/j.jaad.2017.03.022

[87] Garcia Nores GD, Ly CL, Savetsky IL, et al. Regulatory T cells mediate local immunosuppression in lymphedema. J Invest Dermatol. 2018; 138(2): 325–335. https://doi.org/10.1016/j.jid.2017.09.011

[88] Clavin NW, Avraham T, Fernandez J, et al. TGF-beta1 is a negative regulator of lymphatic regeneration during wound repair. Am J Physiol Heart Circ Physiol. 2008; 295(5): H2113–H2127. https://doi.org/10.1152/ajpheart.00879.2008

[89] Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 2018; 19(1): 15. https://doi.org/10.1186/s13059-017-1382-0

[90] Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single-cell data with harmony. Nat Methods. 2019; 16(12): 1289–1296. https://doi.org/10.1038/s41592-019-0619-0

[91] Dominguez Conde C, Xu C, Jarvis LB, et al. Cross-tissue immune cell analysis reveals tissue-specific features in humans. Science. 2022; 376(6594):eabl5197. https://doi.org/10.1126/science.abl5197

[92] Zawieja DC, Thangaswamy S, Wang W, et al. Lymphatic cannulation for lymph sampling and molecular delivery. J Immunol. 2019; 203(8): 2339–2350. https://doi.org/10.4049/jimmunol.1900375

[93] Clement CC, Wang W, Dzieciatkowska M, et al. Quantitative profiling of the lymph node clearance capacity. Sci Rep. 2018; 8(1):11253. https://doi.org/10.1038/s41598-018-29614-0

[94] Broggi MAS, Maillat L, Clement CC, et al. Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. J Exp Med. 2019; 216(5): 1091–1107. https://doi.org/10.1084/jem.20181618

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.